The estimated Net Worth of Peter A Md Demopulos is at least 893 千$ dollars as of 15 November 2023. Peter Demopulos owns over 10,000 units of Omeros stock worth over 767,339$ and over the last 15 years he sold OMER stock worth over 0$. In addition, he makes 125,170$ as Director at Omeros.
Sign up
Peter Demopulos OMER stock SEC Form 4 insiders trading
Peter has made over 9 trades of the Omeros stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of OMER stock worth 15,300$ on 15 November 2023.
The largest trade he's ever made was buying 40,000 units of Omeros stock on 13 May 2011 worth over 198,800$. On average, Peter trades about 4,041 units every 169 days since 2009. As of 15 November 2023 he still owns at least 208,516 units of Omeros stock.
You can see the complete history of Peter Demopulos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Demopulos biography
Dr. Peter A. Demopulos M.D. serves as Director of the Company. Dr. Demopulos has served on our board of directors since January 1995 and on our scientific committee since September 2019. Dr. Demopulos is a practicing board-certified general and interventional cardiologist at Seattle Cardiology, part of the Swedish Heart & Vascular Institute. He has been a member of Seattle Cardiology since 2005, also serving as its Medical Director from 2005 to 2010. Dr. Demopulos is also a clinical assistant professor of cardiology at the University of Washington School of Medicine, a position that he has held since 1989. He also participates as an investigator in clinical trials evaluating interventional cardiology devices and drug therapies at Seattle Cardiovascular Research and Swedish Cardiovascular Research. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University. Our nominating and governance committee has concluded that Dr. Demopulos should continue to serve on the board of directors based on his medical and scientific expertise, his experience as a clinical investigator and his experience with clinical development and trial design, as well as his knowledge of Omeros and our industry. Dr. Demopulos is the brother of Gregory A. Demopulos, M.D., our president and chief executive officer and the chairman of our board of directors.
What is the salary of Peter Demopulos?
As the Director of Omeros, the total compensation of Peter Demopulos at Omeros is 125,170$. There are 12 executives at Omeros getting paid more, with Gregory Demopulos having the highest compensation of 4,825,130$.
How old is Peter Demopulos?
Peter Demopulos is 66, he's been the Director of Omeros since 1995. There are 4 older and 25 younger executives at Omeros. The oldest executive at Omeros Corporation is Ray Aspiri, 83, who is the Independent Director.
What's Peter Demopulos's mailing address?
Peter's mailing address filed with the SEC is 201 ELLIOTT AVENUE WEST, , SEATTLE, WA, 98119.
Insiders trading at Omeros
Over the last 15 years, insiders at Omeros have traded over 719,810$ worth of Omeros stock and bought 141,095 units worth 829,835$ . The most active insiders traders include Gregory A Md Demopulos、Marcia S. Kelbon、Daniel K Spiegelman. On average, Omeros executives and independent directors trade stock every 53 days with the average trade being worth of 97,792$. The most recent stock trade was executed by Gregory A Md Demopulos on 17 November 2023, trading 15,000 units of OMER stock currently worth 25,200$.
What does Omeros do?
omeros is a seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
What does Omeros's logo look like?
Complete history of Peter Demopulos stock trades at Omeros
Omeros executives and stock owners
Omeros executives and other stock owners filed with the SEC include:
-
Gregory Demopulos,
Chairman of the Board, President, Chief Executive Officer -
Dr. Gregory A. Demopulos,
Co-Founder, Chairman, CEO & Pres -
Dr. Gregory A. Demopulos M.D.,
Co-Founder, Chairman, CEO & Pres -
Michael Jacobsen,
Chief Accounting Officer, Vice President - Finance, Treasurer -
Peter Cancelmo,
Vice President, General Counsel, Secretary -
Michael A. Jacobsen,
Chief Accounting Officer, VP of Fin. & Treasurer -
Peter B. Cancelmo J.D.,
VP, Gen. Counsel & Corp. Sec. -
Thomas Bumol,
Independent Director -
Thomas Cable,
Lead Independent Director -
Ray Aspiri,
Independent Director -
Arnold Hanish,
Independent Director -
Leroy Hood,
Independent Director -
Rajiv Shah,
Independent Director -
Peter Demopulos,
Director -
Kurt Zumwalt,
Independent Director -
Timothy Duffy,
Vice President - Business Development -
J. Steven Whitaker,
Vice President, Chief Medical Officer -
Tina Quinton,
Vice President - Patents -
Catherine Melfi,
Vice President - Regulatory Affairs & Quality Systems, Chief Regulatory Officer -
Bruce Meiklejohn,
Vice President - Chemistry, Manufacturing and Controls -
Daniel Kirby,
Vice President, Chief Commercial Officer -
Christopher Bral,
Vice President - Nonclinical Development -
George Gaitanaris,
Chief Scientific Officer, Vice President - Science -
Dr. J. Steven Whitaker J.D., M.D.,
VP of Clinical Devel. & Chief Medical Officer -
Dr. Pamela Pierce Palmer M.D., Ph.D.,
Co-Founder -
Nadia Dac,
Chief Commercial Officer -
Dr. Catherine A. Melfi,
Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems -
Dr. J. Steven Whitaker,
VP of Clinical Devel. & Chief Medical Officer -
Peter W. Williams,
VP of HR -
Dr. George A. Gaitanaris M.D., Ph.D.,
Chief Scientific Officer & VP of Science -
Dr. Pamela Pierce Palmer,
Co-Founder -
Marcia S. Kelbon,
VP Patent and General Counsel -
Diana T. Perkinson,
Director -
Daniel K Spiegelman,
Director -
Jean Philippe Tripet,
Director